Petterson Stephanie C
Arthroscopy. 2025 Feb;41(2):316-317. doi: 10.1016/j.arthro.2024.05.012. Epub 2024 May 25.
Partial-thickness rotator cuff tears (PTRCTs) are difficult to treat. Conservative treatment typically includes physical therapy, nonsteroidal anti-inflammatory drugs, and injectables (e.g., corticosteroid injections, hyaluronic acid, platelet-rich plasma [PRP], stem cells). Recent studies have demonstrated that PRP alone or in combination with other injectables (e.g., PRP + hyaluronic acid) provides a positive short-term therapeutic benefit in patients with PTRCTs. Yet, effects tend to diminish after 1 year. Up to 42% of patients with PTRCTs treated conservatively exhibit tear progression necessitating surgical intervention, and some research shows that PRP may inhibit tendon regeneration. The efficacy and safety of PRP preparations and concentrations can vary, and the optimal biologic injectable and formulation is unknown. Yet, preoperative corticosteroid injections can increase risk of infection after shoulder arthroscopy; thus, continued investigation of biologic injection for rotator cuff tears is indicated.
部分厚度肩袖撕裂(PTRCTs)难以治疗。保守治疗通常包括物理治疗、非甾体抗炎药和注射剂(如皮质类固醇注射、透明质酸、富血小板血浆[PRP]、干细胞)。最近的研究表明,单独使用PRP或与其他注射剂联合使用(如PRP + 透明质酸)在PTRCTs患者中具有积极的短期治疗益处。然而,1年后效果往往会减弱。接受保守治疗的PTRCTs患者中,高达42%会出现撕裂进展,需要手术干预,并且一些研究表明PRP可能会抑制肌腱再生。PRP制剂和浓度的疗效和安全性可能有所不同,最佳的生物注射剂和配方尚不清楚。然而,术前皮质类固醇注射会增加肩关节镜检查后感染的风险;因此,有必要继续研究用于肩袖撕裂的生物注射剂。